Interim Commercial Leadership & Advisory Boards

Accelerating Market Entry With Experienced Leadership

SouthBridge Advisory provides fractional commercial leadership to biopharma companies looking to fast-track their advanced therapy launches. Acting as an Interim Chief Business Officer (CBO) or Commercial Head, we bring senior-level expertise without the overhead of a full-time hire, ensuring your programs move faster from planning to execution.

Our approach

Fractional Leadership Support

Serving as Interim CBO or Commercial Head to provide strategic direction and drive commercialization readiness.

Advisory Boards

Designing and managing advisory boards that bring together key opinion leaders (KOLs), payers, and stakeholders to guide decision-making.

Launch Acceleration

Overseeing go-to-market execution to ensure timelines are met and barriers are resolved quickly.

Cross-Functional Alignment

Coordinating regulatory, medical, supply chain, and commercial teams to operate with efficiency and shared objectives.

why partner with us?

Proven track record of steering CAR-T, biologics, and biosimilars launches in emerging markets.
Access to senior-level expertise without the cost of a permanent executive role.
Ability to accelerate time-to-market through hands-on leadership and decision-making.
Strong experience in building advisory boards with KOLs and payers for clinical adoption and access pathways.

Testimonial

People like us, officially

Trusted by biopharma leaders, medical experts, and investors worldwide for delivering real-world commercialization success in advanced therapies.

SouthBridge’s deep understanding of pricing and access challenges in emerging markets was instrumental in the successful launch of our biologic. Their execution-first approach set them apart from other consultants.

Biopharma Executive Emerging Markets

The team at SouthBridge bridged the gap between science and market strategy. Their KOL engagement framework helped us build strong advocacy and accelerate adoption of our cell therapy

Medical Affairs Director Global CGT Company

SouthBridge’s due diligence and market insights gave us the confidence to invest in a groundbreaking gene therapy. Their practical expertise ensured we had a clear roadmap for commercialization.

Investor Healthcare VC Fund